A Phase 1 study of RC220 combined with doxorubicin in solid tumors
Recruiting Phase 1 NCT06815575
Study Description
A study to evaluate the safety and effectiveness of a new drug called RC220 when combined with doxorubicin in treating advanced solid tumors
Study Details
- Registry ID:
- NCT06815575
- Conditions:
- Solid Tumours, Advanced Solid Tumours
- Phase:
- Phase 1
- Target Enrollment:
- 53 participants
- Start Date:
- Age Range:
- 18–80 years
- Healthy Volunteers:
- No
Study Locations (10 sites)
-
Queen Mary Hospital
Hong Kong, Hong Kong -
Prince of Wales Hospital
Sha Tin, Hong Kong -
Prince of Wales Hospital
Shatin, Hong Kong -
Asan Medical Centre
Seoul, South Korea -
Ewha Womans University MokDong Hospital
Seoul, South Korea -
Samsung Medical Centre
Seoul, South Korea -
Severance Hospital, Yonsei University, Health System
Seoul, South Korea -
Cancer Care Foundation
Miranda, New South Wales, Australia -
Gosford Hospital
Gosford, New South Wales, Australia -
Wyong Hospital
Wyong, New South Wales, Australia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.